Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent

The PD-1:PD-L1 immune checkpoint axis is central in the escape of cancer cells from anticancer immune responses. Monoclonal antibodies (mAbs) specific for PD-L1 have been approved for treatment of various cancer types. Although PD-L1 blockade has proven its merit, there are still several aspects tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Broos, Katrijn, Lecocq, Quentin, Xavier, Catarina, Bridoux, Jessica, Nguyen, Tham T., Corthals, Jurgen, Schoonooghe, Steve, Lion, Eva, Raes, Geert, Keyaerts, Marleen, Devoogdt, Nick, Breckpot, Karine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628009/
https://www.ncbi.nlm.nih.gov/pubmed/31234464
http://dx.doi.org/10.3390/cancers11060872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628009/
https://www.ncbi.nlm.nih.gov/pubmed/31234464
http://dx.doi.org/10.3390/cancers11060872

Ejemplares similares